High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme-Reference-Cited by-同舟云学术

High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme

Published:2014-11-04 Issue:3 Volume:15 Page:288-292
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Apellániz-Ruiz M,Inglada-Pérez L,Naranjo M E G,Sánchez L,Mancikova V,Currás-Freixes M,de Cubas A A,Comino-Méndez I,Triki S,Rebai A,Rasool M,Moya G,Grazina M,Opocher G,Cascón A,Taboada-Echalar P,Ingelman-Sundberg M,Carracedo A,Robledo M,Llerena A,Rodríguez-Antona C

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/tpj201467.pdf

Reference24 articles.

1. Zanger UM, Schwab M . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103–141.

2. Nebert DW, Russell DW . Clinical importance of the cytochromes P450. Lancet 2002; 360: 1155–1162.

3. Schuetz EG . Lessons from the CYP3A4 promoter. Mol Pharmacol 2004; 65: 279–281.

4. Haddad A, Davis M, Lagman R . The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007; 15: 251–257.

5. Badyal DK, Dadhich AP . Cytochrome P450 and drug interactions. Indian J Pharmacol 2001: 248–259.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ziprasidone population pharmacokinetics and co-medication effects in Chinese patients;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-06-25

2. Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example;Pharmaceuticals;2024-04-08

3. SLCO1B1 and CYP3A4 allelic variants associated with pharmacokinetic interactions and adverse reactions induced by simvastatin and atorvastatin used in Peru: Clinical implications;Journal of Pharmacy & Pharmacognosy Research;2023-11-01

4. CYP3A4 and CYP3A5 Genotyping Recommendations;The Journal of Molecular Diagnostics;2023-09

5. Identification of Drugs Acting as Perpetrators in Common Drug Interactions in a Cohort of Geriatric Patients from Southern Italy and Analysis of the Gene Polymorphisms That Affect Their Interacting Potential;Geriatrics;2023-08-24